KemPharm (KMPH) Misses Q2 EPS by 56c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equities rebound to close higher as surging Treasury yields recede
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
August 11, 2022 4:05 PM EDTConference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET
Perry Sternberg, Corium, Inc.s President and CEO, to Participate and Provide Update on the Commercialization of AZSTARYS®
Acquired substantially all the assets and operations of Orphazyme A/S, including arimoclomol, for a cash payment of $12.8 millionResubmission of the arimoclomol NDA for the treatment of NPC as early as Q1 2023Filed IND application for KP1077,... More